T 1038/14 of 22.06.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T103814.20180622
- Date of decision
- 22 June 2018
- Case number
- T 1038/14
- Online on
- 21 May 2019
- Petition for review of
- -
- Application number
- 01270333.6
- IPC class
- A61K 31/565A61P 5/24
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- USE OF AN OESTROGEN IN THE MANUFACTURE OF A COMPOSITION CONTAINING OESTROGEN FOR THE TREATMENT OF ATROPHIC VAGINITIS
- Applicant name
- Novo Nordisk Health Care AG
- Opponent name
- Laboratorios Léon Farma, S.A.
Helm AG - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(b)European Patent Convention Art 113(1)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention R 103(1)(a)European Patent Convention R 111(2)Rules of procedure of the Boards of Appeal Art 11
- Keywords
- Right to be heard - substantial procedural violation (yes)
Right to be heard - decision under appeal insufficiently reasoned
Reimbursement of appeal fee - (yes)
Remittal to the department of first instance - special reasons for not remitting the case
Grounds for opposition - insufficiency of disclosure (yes)
Grounds for opposition - main request
Novelty - second (or further) medical use (yes)
Inventive step - (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The request for reimbursement of the appeal fee of appellant-opponent 2 is allowed.